HIV/AIDS

Antiretroviral therapy for HIV prevention consultation

AGENDA: Day 1

OPENING SESSION
09:00 Welcome and opening remarks
Hiroki Nakatani
09:15 Background [pdf 810kb]
Teguest Guerma
Meeting objectives, expected outcomes and working methods [pdf 176kb]
Siobhan Crowley
09:30 Universal voluntary HIV testing and counselling and immediate ART: results of a modelling exercise
[pdf 1.26Mb] Brian Williams | [pdf 2.09Mb] Reuben Granich
SCIENTIFIC AND TECHNICAL CONSIDERATIONS
Chair: Kevin M. De Cock
11:00 Universal voluntary testing and treatment: when to start and other research issues [pdf 3.81Mb]
Carl Dieffenbach
Scientific evidence for the use of ART for HIV prevention [pdf 979kb]
Julio Montaner
Commentary [pdf 282kb]
Myron Cohen
12:00 Scientific evidence on HIV testing and counselling to prevent HIV transmission and increase access to prevention, treatment and care
[pdf 2.13Mb] Michael Sweat | [pdf 2.48Mb] Susan Allen
ETHICAL, HUMAN RIGHTS AND COMMUNITY CONSIDERATIONS
Chair: Beri Hull
14:00 Community engagement and acceptance of ART for HIV prevention
Nonkosi Khumalo
People living with HIV perspectives on ART for HIV prevention [pdf 166kb]
Kevin Moody
Human rights and ART for prevention
Lucy Cheshire
Gender perspectives on ART for HIV prevention
Mariangela Simao
Ethics of ART for HIV prevention as a public health intervention [pdf 120kb]
Khoudia Sow
OPERATIONAL CONSIDERATIONS - ECONOMIC AND HEALTH SYSTEMS ISSUES
Chair: Wafaa El-Sadr
16:30 UNAIDS/WHO assumptions, methods and estimation of resource needs to achieve universal access [pdf 687kb]
Carlos Avila
Costs of scaling up and the current financial landscape [pdf 491kb]
Tessa Edejer
Detailed programme costing of seek and immediately treat approaches in a hyperendemic setting [pdf 352kb]
Jim Kahn
Commentary: The Global Fund perspective
Rifat Atun
Commentary: The PEPFAR perspective
Eric Goosby

Share